Evogene Ltd. Shareholders Approve Key Proposal
Ticker: EVGN · Form: 6-K · Filed: Feb 12, 2025 · CIK: 1574565
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting
TL;DR
Evogene shareholders greenlit a proposal on Feb 12th after a delay; details TBD.
AI Summary
Evogene Ltd. announced on February 12, 2025, that its shareholders approved a proposal at a special general meeting. This meeting was originally scheduled for a week prior but was adjourned. The specific details of the approved proposal were not disclosed in this filing.
Why It Matters
Shareholder approval of proposals is crucial for a company's strategic direction and operational changes, potentially impacting its future performance and stock value.
Risk Assessment
Risk Level: low — This filing is a routine corporate announcement regarding shareholder meeting outcomes and does not contain significant financial or operational risks.
Key Players & Entities
- Evogene Ltd. (company) — Registrant
- February 12, 2025 (date) — Date of shareholder meeting
FAQ
What specific proposal was approved by Evogene Ltd. shareholders?
The filing states that shareholders approved a proposal brought before the special general meeting, but the specific details of the proposal are not disclosed in this document.
When was the special general meeting of Evogene Ltd. shareholders held?
The special general meeting of shareholders was held on February 12, 2025.
Was the shareholder meeting held on its originally scheduled date?
No, the meeting held on February 12, 2025, followed a one-week adjournment from the original meeting date.
What is the primary purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, announcing material information.
Where is Evogene Ltd. headquartered?
Evogene Ltd. is headquartered at 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel.
Filing Stats: 325 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2025-02-12 16:01:54
Filing Documents
- zk2532711.htm (6-K) — 13KB
- 0001178913-25-000437.txt ( ) — 14KB
From the Filing
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File Number 001-36187 EVOGENE LTD. (Translation of Registrant's Name into English) 13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F CONTENTS Evogene Ltd. (the " Registrant " or the " Company ") hereby announces that the shareholders of the Company approved the proposal brought before the special general meeting of shareholders held on February 12, 2025 (following a one-week adjournment from the original meeting date) (the " Meeting "), by the respective requisite majority in accordance with the Israeli Companies Law, 5759-1999, and the Company's articles of association, as described in the Proxy Statement which was attached as Exhibit 99.2 to the Company's Report of Foreign Private Issuer on Form 6-K, furnished to the Securities and Exchange Commission (" SEC "), on December 30, 2024, and sent in connection with the Meeting. The contents of this Report of Foreign Private Issuer on Form 6-K (this " Form 6-K ") is incorporated by reference in the registration statements on Form F-3 (SEC File No. 333-277565 ), and Form S-8 (SEC File Nos. 333-193788 , 333-201443 , 333-203856 and 333-259215 ) of the Company, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: February 12, 2025 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad —————————————— Yaron Eldad Chief Financial Officer